Influence of ethinylestradiol-containing
β
A. Balogh; L. Henschel; G. Klinger; R. Vollanth; A. BΓΆrner; W. Kuhnz
π
Article
π
1995
π
Springer
π
English
β 603 KB
In a controlled clinical trial, the elimination of caffeine was examined in 20 healthy women prior to and during one cycle of treatment with either of two oral contraceptive formulations, one containing 0.075 mg gestodene and 0.03 mg ethinylestradiol and one containing 0.125 mg levonorgestrel and 0.